Drugs / UTAA09 injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06503211 | Jul 2024 → Jul 2025 overdue | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTAA09 injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06503211 ↗ |
| Modality | Cell therapy | “CD19-CAR - γδT cells” NCT06503211 ↗ |
| Target | CD19 | “B cell injection targeting CD19 chimeric antigen receptor” NCT06503211 ↗ |